Intrahepatic Cholestasis of Pregnancy and Associated Adverse Maternal and Fetal Outcomes: A Retrospective Case-Control Study

Mingjuan Luo,1,2,3 Mengyang Tang,1,2 Feng Jiang,4 Yizhen Jia,5 Robert Kien Howe Chin,6 Wei Liang,3 and Hu Cheng1,2,4

1The Third School of Clinical Medicine, Southern Medical University, Guangzhou, 510000 Guangdong, China
2Department of Endocrinology and Metabolism, Fengxian Central Hospital Affiliated to the Southern Medical University, Shanghai 201499, China
3Department of Endocrinology and Metabolism, The University of Hong Kong-Shenzhen Hospital, Shenzhen, 518053 Guangdong, China
4Shanghai Diabetes Institute, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai 200233, China
5Core Laboratory, The University of Hong Kong-Shenzhen Hospital, Shenzhen, 518053 Guangdong, China
6Department of Obstetrics and Gynecology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, 518053 Guangdong, China

Correspondence should be addressed to Wei Liang; liangw@hku-szh.org and Hu Cheng; alfredhc@sjtu.edu.cn

Received 27 October 2020; Revised 2 February 2021; Accepted 10 March 2021; Published 25 March 2021

Academic Editor: Fabiana Zingone

Copyright © 2021 Mingjuan Luo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. Intrahepatic cholestasis of pregnancy (ICP) is a common pregnancy-related liver disease and is associated with an increased risk of adverse neonatal outcomes. Ursodeoxycholic acid (UDCA) is the most effective treatment. This study was aimed at investigating the adverse outcomes of ICP and evaluating the effects of treatment with UDCA in patients with ICP.

Methods. We included 114 women with ICP and 3725 women without ICP (no-ICP group) who delivered in our hospital between September 2017 and August 2019. The prevalence of ICP in this study was 3.15%. We matched each woman with ICP to five controls. Of all the 114 women with ICP, 73 (64.04%) received UDCA while 41 (35.96%) did not. Logistic multivariate regression analysis was used to compare the adverse outcomes between those with ICP and matched controls as well as between those who received UDCA (UDCA group) and those who did not (non-UDCA group).

Results. Compared with controls, women with ICP were more likely to have preeclampsia (adjusted odds ratio, aOR = 16.74, 95% CI 5.29–52.98), cesarean section (aOR = 1.76, 95% CI 1.10–2.81), and preterm birth (aOR = 24.35, 95% CI 2.74–216.67). Administration of UDCA reduced the rate of preterm birth (1.37% vs. 14.63%, aOR = 0.10, 95% CI 0.01–0.90).

Conclusion. ICP increased the risk of preeclampsia, cesarean section, and preterm birth. UDCA could reduce the rate of preterm birth.

1. Introduction

Intrahepatic cholestasis of pregnancy (ICP) is the most common pregnancy-related liver disorder [1, 2]. Clinically, ICP is characterized by pruritus without rash and increased bile acid levels in the late second and/or early third trimester, which rapidly resolve after delivery. The incidence of ICP varies widely from 0.1% to 15.6% and is influenced by geographic variations, ethnicity, and environmental factors [3–6]. Risk factors for ICP include personal or family history of ICP, multiple pregnancy, history of cholelithiasis, in vitro fertilization, and history of hepatitis C virus infection [7, 8].

Although ICP is generally a benign disease, it can result in adverse neonatal outcomes [9]. In a Swedish cohort study, fetal complications, including spontaneous preterm labor, meconium-stained amniotic fluid, and fetal asphyxia, were observed only in patients with ICP with bile acid levels ≥ 40 μmol/l [10]. A prospective study in the United Kingdom also concluded that women with severe ICP (total bile acids (TBA) ≥ 40 μmol/l) have increased risks of preterm delivery, neonatal unit admission, and stillbirth compared to controls [11]. While some studies have demonstrated an association of ICP with increased maternal risks including preeclampsia, impaired glucose tolerance,
and dyslipidemia [12–15], most research has focused on the neonatal outcomes of ICP and investigations concerning the mothers are limited.

Treatment with ursodeoxycholic acid (UDCA) has been effective in reducing pruritus and improving liver function and is generally recommended in the treatment of ICP [16]. However, a recent placebo-controlled trial in women with ICP showed that UDCA did not improve the primary composite outcome of perinatal death, preterm delivery or neonatal unit admission, or secondary maternal outcomes [17].

Hence, in this study, we aimed to retrospectively evaluate the maternal and neonatal outcomes of ICP in our hospital and to evaluate the effects of UDCA in women with ICP. Moreover, several studies provided evidence that normal pregnancy is mildly cholestatic [18–20]. As elevated bile acid level is the hallmark of ICP, we hypothesized that TBA level is also related to adverse pregnancy outcomes even in women without ICP. Thus, we also investigated the correlations between TBA and relevant indices in women without ICP in this study.

2. Methods

This study was conducted in the University of Hong Kong-Shenzhen Hospital, Shenzhen, China. A total of 4287 women who delivered between September 2017 and August 2019 were included in this study. Women who did not have data for TBA levels were excluded. ICP was diagnosed based on the association of otherwise unexplained pruritus with elevated TBA (≥10 μmol/l). Exclusion criteria included conditions associated with abnormal liver function tests. Women with multiple pregnancies were also excluded. The exclusion criteria for controls (no-ICP group) were the same as those for the ICP group. A total of 114 women with ICP and 3725 women without ICP were included in the final analysis. To improve the power of the study, each woman with ICP was matched to five controls based on maternal age (±3 years), gestational body mass index (BMI) (±3 kg/m²), and gestational age during bile acid measurement (±3 weeks). Furthermore, the ICP group was subdivided according to the use of UDCA into UDCA and non-UDCA groups. UDCA was recommended for all women with ICP, and treatment was initiated after obtaining informed consent. Each participant provided written informed consent before participating in this study. This study was approved by the Medical Ethics Committee of the University of Hong Kong-Shenzhen Hospital.

For the reliability and validation of the database, the data were entered by the first author and verified by another author. The following data were extracted from the electronic database: maternal age, pregestational BMI, and blood pressure in the first trimester; therapeutic approach; obstetric outcomes, including gestational age, neonatal birth weight, and mode of delivery; and clinical maternal and neonatal outcomes. Maternal adverse outcomes included cesarean section, preeclampsia, gestational diabetes mellitus (GDM), polyhydramnios, oligohydramnios, postpartum hemorrhage, and puerperal infection. Preeclampsia referred to the new onset of hypertension (systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg on at least two occasions at least 4 hours apart) and proteinuria after 20 weeks of gestation [21, 22]. GDM was diagnosed based on the following blood glucose readings: fasting plasma glucose ≥ 5.1 mmol/l, 1 h postprandial glucose ≥ 10.0 mmol/l, or 2 h postprandial glucose ≥ 8.5 mmol/l during a 75 g oral glucose tolerance test (OGTT) at 24–28 weeks of gestation [23]. Postpartum hemorrhage was defined as blood loss > 500 ml within 24 h after delivery [24]. Neonatal adverse outcomes included macrosomia (weight ≥ 4 kg), fetal distress, preterm birth (gestational age < 37 weeks), stillbirth, and fetal malformation.

Data on serum biochemical parameters, such as OGTT in the second trimester, and maximum serum fasting TBA level, were also obtained. Blood glucose was measured using the hexokinase method on a Roche Cobas 701 biochemical analyzer (Roche, Ltd., Basel, Switzerland). TBA level was determined using an enzymatic cycling method on a Roche Cobas 701 analyzer (Purebio, Ltd., Ningbo, China).

Data analysis was performed by SPSS version 26.0 (IBM SPSS, Corp., Armonk, USA). Quantitative data were expressed as means ± SD or as medians with interquartile ranges using Student’s t-test or Mann-Whitney U test, as appropriate. Logistic regression analysis was employed to estimate the risk of adverse maternal and neonatal outcomes in relation to ICP by odds ratios (OR) with 95% confidence intervals (CI), considering possible confounding factors, such as maternal age, pregestational BMI, TBA level, and preeclampsia. Logistic regression analysis was also performed to examine the associations of TBA levels with adverse pregnancy outcomes in the no-ICP group. The correlations between TBA level and relevant parameters were estimated by the Spearman or Pearson correlation analysis according to the distribution of relevant variables. A two-tailed P < 0.05 was considered statistically significant.

3. Results

Of 4287 women who delivered from September 2017 to August 2019 in the University of Hong Kong-Shenzhen Hospital, we excluded 376 women with missing data for TBA levels, 8 women with multiple pregnancies and ICP, and 57 women with multiple pregnancies without ICP. After matching to controls, 114 women with ICP were included in the final analysis (Figure 1).

3.1. Characteristics of Subgroups. The majority of the 114 women with ICP received UDCA (73, 64.04%). Table 1 shows the clinical characteristics of the ICP group and controls. Table 2 shows the clinical characteristics of the UDCA and non-UDCA groups. No significant differences in maternal age, pregestational BMI, systolic blood pressure, diastolic blood pressure, and OGTT were found between the ICP group and controls or between the UDCA and non-UDCA groups (Tables 1 and 2). The ICP group had higher TBA levels (median 20.23 μmol/l) than the controls (median 28.20 μmol/l) (P < 0.05; Table 1). The TBA levels between the UDCA and non-UDCA groups were similar (P > 0.05; Table 2).
3.2. Adverse Maternal and Neonatal Effects in the ICP Group and Controls.

Women with ICP delivered earlier than the controls (P < 0.05; Table 1). Infants of women with ICP had a lower birth weight than those of the controls (P < 0.05; Table 1). Women with ICP had higher rates of preeclampsia, cesarean section, and preterm birth using univariate logistic regression analysis (Table 3). These differences were also significant in multivariate logistic regression analysis (Figure 2). As shown in Figure 2, women with ICP were more likely to have preeclampsia (aOR = 16.74, 95% CI 5.29–52.98), cesarean section (aOR = 1.76, 95% CI 1.10–2.81), and preterm birth (aOR = 24.35, 95% CI 2.74–216.67) than controls. Nevertheless, no significant differences in GDM, polyhydramnios, oligohydramnios, postpartum hemorrhage, puerperal infection, macrosomia, fetal distress, and fetal malformation were observed between the two groups.

![Flowchart of the study](image)

**Table 1: Characteristics of ICP and control groups.**

| Characteristics | ICP          | Control     | P value |
|-----------------|--------------|-------------|---------|
| N               | 114          | 570         |         |
| Age (years)     | 30.00 (28.00, 34.00) | 30.00 (28.00, 33.00) | 1.00    |
| Pregestational BMI (kg/m²) | 19.77 (18.65, 20.96) | 19.69 (18.59, 20.96) | 0.83    |
| SBP (mmHg)      | 107.00 (101.00, 113.00) | 107.00 (100.00, 114.00) | 0.81    |
| DBP (mmHg)      | 66.00 (60.00, 72.00) | 66.00 (60.00, 72.00) | 0.91    |
| 0hBG (mmol/l)   | 4.33 (4.13, 4.62) | 4.40 (4.18, 461) | 0.39    |
| 1hBG (mmol/l)   | 7.69 (6.70, 9.02) | 7.65 (6.52, 8.86) | 0.39    |
| 2hBG (mmol/l)   | 6.57 (5.77, 7.49) | 6.61 (5.87, 7.76) | 0.60    |
| Total bile acid (μmol/l) | 20.23 (14.63, 28.32) | 2.20 (1.63, 3.04) | 1.22E – 63 |
| Gestational age at delivery (weeks) | 39.00 (38.00, 39.57) | 39.71 (39.14, 40.43) | 3.62E – 13 |
| Birth weight (g) | 3100.00 ± 427.31 | 3270.00 ± 352.28 | 2.06E – 4 |

Data are presented as means ± SD or as medians with the interquartile ranges. ICP — patients with bile acids > 10 μmol/l. ICP: intrahepatic cholestasis of pregnancy; SBP: systolic blood pressure; DBP: diastolic blood pressure; OGTT: oral glucose tolerance test; 0hBG: 0 h postprandial blood glucose; 1hBG: 1 h postprandial blood glucose; 2hBG: 2 h postprandial blood glucose.
3.3. Adverse Maternal and Neonatal Effects in the UDCA and Non-UDCA Groups. The gestational age at delivery was higher in the UDCA group than in the non-UDCA group ($P < 0.05$; Table 2). Univariate and multivariate logistic regression analyses showed that the rate of preterm birth was reduced in those who received UDCA compared with those who did not (aOR = 0.10, 95% CI 0.01–0.90). However, the administration of UDCA did not decrease the rate of preeclampsia or cesarean section (Table 4).

3.4. Relationship between Total Bile Acid and Adverse Pregnancy Outcomes in Women without ICP. Univariate logistic regression analysis demonstrated that the TBA level was associated with preeclampsia (OR = 1.19, 95% CI 1.08–1.31) and preterm birth (OR = 1.23, 95% CI 1.10–1.38) (Table 5), but not with cesarean section. Furthermore, multivariate logistic regression analysis also indicated that pre-eclampsia (aOR = 1.18, 95% CI 1.07–1.32) and preterm birth (aOR = 1.22, 95% CI 1.08–1.37) were related to TBA level in women without ICP ($n = 3725$) (Table 5).

3.5. Correlation between Total Bile Acid and Relevant Indices in Women without ICP. The correlations between TBA level and relevant indices in women without ICP ($n = 3725$) were estimated by the Spearman correlation analysis. The TBA level was negatively correlated with gestational age (correlation coefficient = −0.03, $P = 0.04$) but not with neonatal weight or maternal age (Table 6).

4. Discussion

The prevalence of ICP in this study was 3.15%, which was lower than that of other domestic studies [25]. A possible reason for this may be due to our comprehensive evidence-based management of patients with ICP and their good compliance. This retrospective study indicated that ICP increased

### Table 2: Characteristics of UDCA and non-UDCA groups.

| Characteristics | Non-UDCA | UDCA | $P$ value |
|-----------------|----------|------|-----------|
| N               | 41       | 73   |           |
| Age (years)     | 30.00 (28.00, 34.00) | 30.00 (28.00, 33.00) | 0.99 |
| Pregestational BMI (kg/m$^2$) | 19.92 (18.59, 21.01) | 19.71 (18.73, 20.76) | 0.42 |
| SBP (mmHg)      | 108.00 (101.50, 115.50) | 107.00 (100.50, 112.00) | 0.19 |
| DBP (mmHg)      | 66.00 (61.50, 75.00) | 66.00 (59.00, 70.00) | 0.14 |
| 0hBG (mmol/l)   | 4.36 (4.19, 4.62) | 4.33 (4.08, 4.61) | 0.33 |
| 1hBG (mmol/l)   | 7.77 (6.75, 8.77) | 7.65 (6.70, 9.17) | 0.75 |
| 2hBG (mmol/l)   | 6.61 (6.18, 7.34) | 6.49 (5.68, 7.58) | 0.87 |
| Total bile acid (μmol/l) | 19.71 (12.87, 27.78) | 21.66 (15.37, 28.32) | 0.53 |
| Gestational age at delivery (weeks) | 38.57 (37.86, 39.29) | 39.14 (38.43, 39.86) | 0.01 |
| Birth weight (g) | 3130.00 ± 395.03 | 3050.00 ± 480.67 | 0.36 |

Data are presented as means ± SD or as medians with the interquartile ranges. UDCA—patients with ICP who received UDCA; non-UDCA—patients with ICP who did not use UDCA. UDCA: ursodeoxycholic acid.

### Table 3: Adverse effects in ICP and controls (n (%)).

|                      | Control ($n = 570$) | ICP ($n = 114$) | Univariate analysis | Multivariate analysis |
|----------------------|---------------------|-----------------|---------------------|-----------------------|
|                      | OR                  | 95% CI          | $P$ value           | aOR                   | 95% CI          | $P$ value           |
| Preeclampsia         | 4 (0.70)            | 12 (10.53)      | 16.65               | 5.27-52.63            | $2E - 6$        |
| Cesarean section     | 125 (21.93)         | 40 (35.09)      | 1.92                | 1.25-2.97             | $3E - 3$        |
|                      | 3E                |                 | 1.76                | 1.10-2.81             | 1.9E           |
| GDM                  | 117 (20.53)         | 21 (18.42)      | 0.87                | 0.52-1.46             | 0.61            |
|                      | 1.00               |                 | 1.00                | 1.00                  | 1.00            |
| Polyhydramnios       | 2 (0.35)            | 0 (0)           | 0.00                | 0.00                  | 1.00            |
| Oligohydramnios      | 5 (0.88)            | 1 (0.88)        | 1.00                | 0.12-8.64             | 1.00            |
| Postpartum hemorrhage| 4 (0.70)            | 0 (0)           | 0.00                | 0.00                  | 1.00            |
|                      | 0.00               |                 | 1.00                | 1.00                  | 1.00            |
| Puerperal infection  | 4 (0.70)            | 0 (0)           | 0.00                | 0.00                  | 1.00            |
|                      | 0.00               |                 | 1.00                | 1.00                  | 1.00            |
| Preterm birth        | 1 (0.18)            | 7 (6.14)        | 37.22               | 4.53-305.64           | $1E - 3$        |
|                      | 24.35              |                 | 2.74-216.67         | 4E                   |
| Macrosomia           | 16 (2.81)           | 3 (2.63)        | 0.94                | 0.27-3.27             | 0.92            |
| Fetal distress       | 5 (0.88)            | 3 (2.63)        | 3.05                | 0.72-12.97            | 0.13            |
| Fetal malformation   | 1 (0.18)            | 0 (0)           | 0.00                | 0.00                  | 1.00            |
| Stillbirth           | 0 (0)               | 0 (0)           | 0.00                | 0.00                  | 1.00            |

ICP—patients with bile acids > 10 μmol/l. ICP: intrahepatic cholestasis of pregnancy; GDM: gestational diabetes mellitus.
the rate of cesarean section, preeclampsia, and preterm birth and that UDCA could reduce the rate of preterm birth. Moreover, we found that TBA was associated with preeclampsia in women without ICP. Studies on the association between ICP and preeclampsia are scarce, and most published studies have been reported as cases or small summaries only [26, 27]. Preeclampsia was used as an exclusion criterion in prospective ICP studies [10]. In 2013, a cohort study conducted in Sweden was the first to reveal that women with ICP were more likely to have preeclampsia (OR 2.62, 95% CI 2.32-2.78) than those without ICP [15]. In a recent retrospective study from Israel, the incidence of preeclampsia was higher in women with ICP than in the reference group (aOR 3.74, 95% CI 2.0-7.02) [28]. The association between ICP and preeclampsia could be because they share similar

---

**Table 4: Adverse effects in UDCA and non-UDCA (n (%)).**

|                  | UDCA (N = 73) | Non-UDCA (N = 41) | Univariate analysis | Multivariate analysis |
|------------------|---------------|-------------------|--------------------|----------------------|
|                  | OR            | 95% CI            | P value            | aOR                  | 95% CI | P value |
| Preeclampsia     | 6 (8.22)      | 6 (14.63)         | 0.52               | 0.16-1.74            | 0.29   | —       | —       |
| Cesarean section | 22 (30.14)    | 18 (43.90)        | 0.56               | 0.25-1.25            | 0.16   | —       | —       |
| Preterm birth    | 1 (1.37)      | 6 (14.63)         | 0.08               | 0.01-0.70            | 0.02   | 0.10    | 0.01-0.90 | 0.04 |

ICP—patients whose bile acids are above 10 μmol/l. ICP: intrahepatic cholestasis of pregnancy.

---

**Table 5: Logistic analysis of total bile acid and adverse pregnancy outcomes in women without ICP.**

|                  | Univariate analysis | Multivariate analysis |
|------------------|---------------------|----------------------|
|                  | OR                  | 95% CI               | P value | aOR | 95% CI | P value |
| Preeclampsia     | 1.19                | 1.08-1.31            | 1E - 3  | 1.18 | 1.07-1.32 | 2E - 3  |
| Premature birth  | 1.23                | 1.10-1.38            | 2.82E - 4 | 1.22 | 1.08-1.37 | 3.41E - 4 |
| Cesarean section | 1.02                | 0.97-1.07            | 0.48    | —   | —       | —       |

ICP—patients with bile acids > 10 μmol/l. ICP: intrahepatic cholestasis of pregnancy.
Women without ICP.

normal controls. Under such a protocol, the rate of cesarean section is higher in ICP than in normal controls.

In our study, women with ICP had a higher rate of preterm birth, which is consistent with previous research. A meta-analysis showed that the rate of preterm birth increased in women with ICP with TBA level ≥ 40 µmol/l compared to women with lower bile acid levels [35]. In a recent meta-analysis, women with ICP (n = 5557) had higher OR of preterm birth (OR 3.54, 95% CI 2.72–4.62) than healthy controls (n = 165,136) [36], and iatrogenic preterm birth was a major contributor to the prevalence of preterm birth in ICP and occurred more commonly than that in controls. However, the precise mechanism of preterm birth due to ICP has not been clearly established; nevertheless, elevated TBA possibly influences myometrial contraction, which leads to increased preterm birth in ICP, as suggested by in vivo and in vitro data. In rodents, a dose-dependent effect of bile acids on myometrial contractility has been observed [37]. In addition, myometrial cells from women with ICP were more responsive to oxytocin than those from women without ICP [38]. In our study, we also found that TBA was associated with preterm birth in the no-ICP group, which could be attributed to the mechanism of TBA in pregnancy.

Stillbirth is the most severe outcome that could be induced by ICP. In our study, no stillbirth was observed, which is not surprising as this outcome is very rare according to previous reports [39]. In a recent meta-analysis, stillbirth occurred in 0.83% of ICP cases, and the risk of stillbirth is increased in women with a singleton pregnancy and ICP with serum bile acid levels ≥ 100 µmol/l [36]. In our study, the highest TBA level recorded was 87.01 µmol/l, partially explaining the absence of stillbirth in our study. Nonetheless, the risk of stillbirth seems to increase after 37 weeks [40]. To prevent stillbirth in patients with ICP [5], obstetric interventions are performed, which could in turn result in higher rates of preterm birth and cesarean section.

UDCA is the mainstay of treatment for ICP. In an 8-year case-control study in France, UDCA was administered to 43.6% of women with ICP and its prescription rate increased with the severity of bile acid elevation [41]. Our study showed that 64.04% of women with ICP were administered UDCA, with the severity of bile acid elevation [41]. In our study, we also found that UDCA was associated with a decrease in the rate of premature birth (OR 0.44, 95% CI 0.24–0.79), neonatal respiratory distress (OR 0.49, 95% CI 0.12–0.74), and neonatal admission to the intensive care unit (OR 0.49, 95% CI 0.25–0.98) when compared with controls. However, no difference in fetal outcomes was found between UDCA and placebo treatments [43]. Moreover, a recent placebo-controlled trial that enrolled 305 women with ICP receiving UDCA and 300 receiving placebo concluded that treatment with UDCA does not benefit the mother nor the fetus [17]. However, after updating the Cochrane systematic

### Table 6: Correlation of total bile acid with relevant indices in women without ICP.

|                    | Gestational age | Neonatal weight | Maternal age |
|--------------------|-----------------|-----------------|--------------|
| Correlation coefficient | -0.03          | 0.02            | -0.018       |
| P value            | 0.04            | 0.23            | 0.26         |

ICP—patients with bile acids > 10 µmol/l. ICP: intrahepatic cholestasis of pregnancy.
review with this trial and four others on preterm birth [44–47], a significant reduction in total preterm birth, probably iatrogenic deliveries, was observed with UDCA treatment. A similar result was found in our study; that is, treatment with UDCA did not decrease the adverse outcomes except preterm delivery. This finding enhances our confidence in prescribing UDCA to patients with ICP to reduce preterm birth.

This study has several strengths including the comparison of comprehensive maternal and neonatal outcomes of ICP and the evaluation of UDCA in decreasing the adverse outcomes. Moreover, we explored the correlation of TBA with adverse pregnancy outcomes in the no-ICP group. However, it also has some limitations. First, this study is retrospective. Second, we did not distinguish emergency from elective cesarean section. Lastly, this is a single-center study, and the number of subjects was small. Hence, further prospective studies with a larger sample size are warranted to further explore the effect of TBA and ICP during pregnancy.

In conclusion, ICP could result in preeclampsia, cesarean section, and preterm birth. Furthermore, UDCA could decrease the preterm birth rate. Further larger prospective studies are required to determine the adverse effect of ICP during pregnancy and the efficacy of UDCA.

Data Availability
Data are available on request.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

Authors’ Contributions
Mingjuan Luo (female, born in 1983, master, associate chief physician, research interest is endocrinology and metabolism) contributed equally to this work.

Acknowledgments
This work was supported by the High-level Hospital Program, Health Commission of Guangdong Province, China (HKUSZH201901025); the project from Shanghai Diabetes Key Laboratory (SHKLD-KF-1701); the National Key Research and Development Project of China (2016YFC1304902); the National Science Foundation of China (81570713 and 91649112); and the Outstanding Academic Leaders of Shanghai Health System (2017BR008).

References
[1] P. H. Dixon and C. Williamson, “The pathophysiology of intrahepatic cholestasis of pregnancy,” Clinics and Research in Hepatology and Gastroenterology, vol. 40, no. 2, pp. 141–153, 2016.
[2] D. Joshi, A. James, A. Quaglia, R. H. Westbrook, and M. A. Heneghan, “Liver disease in pregnancy,” The Lancet, vol. 375, no. 9714, pp. 594–605, 2010.
[3] S. Ozkan, Y. Ceylan, O. V. Ozkan, and S. Yildirim, “Review of a challenging clinical issue: intrahepatic cholestasis of pregnancy,” World Journal of Gastroenterology, vol. 21, no. 23, pp. 7134–7141, 2015.
[4] A. M. Allen, W. R. Kim, J. J. Larson et al., “The epidemiology of liver diseases unique to pregnancy in a US community: a population-based study,” Clinical Gastroenterology and Hepatology, vol. 14, no. 2, pp. 287–294.e2, 2016.
[5] J. A. Marathe, W. H. Lim, M. P. Metz, W. Scheil, G. A. Dekker, and W. M. Hague, “A retrospective cohort review of intrahepatic cholestasis of pregnancy in a South Australian population,” European Journal of Obstetrics, Gynecology, and Reproductive Biology, vol. 218, pp. 33–38, 2017.
[6] M. Rook, J. Vargas, A. Caughney, P. Bacchetti, P. Rosenthal, and L. Bull, “Fetal outcomes in pregnancies complicated by intrahepatic cholestasis of pregnancy in a Northern California cohort,” PLoS One, vol. 7, no. 3, pp. e28343–e28348, 2012.
[7] C. Williamson and V. Geenes, “Intrahepatic cholestasis of pregnancy,” Obstetrics and Gynecology, vol. 124, no. 1, pp. 120–133, 2014.
[8] H. U. Marschall, E. Wikström Shemer, J. F. Ludvigsson, and O. Stephansson, “Intrahepatic cholestasis of pregnancy and associated hepatobiliary disease: a population-based cohort study,” Hepatology, vol. 58, no. 4, pp. 1385–1391, 2013.
[9] V. Geenes and C. Williamson, “Intrahepatic cholestasis of pregnancy,” World Journal of Gastroenterology, vol. 15, no. 17, pp. 2049–2066, 2009.
[10] A. Glantz, H.-U. Marschall, and L.-Å. Mattsson, “Intrahepatic cholestasis of pregnancy: relationships between bile acid levels and fetal complication rates,” Hepatology, vol. 40, no. 2, pp. 467–474, 2004.
[11] V. Geenes, L. C. Chappell, P. T. Seed, P. J. Steer, M. Knight, and C. Williamson, “Association of severe intrahepatic cholestasis of pregnancy with adverse pregnancy outcomes: a prospective population-based case-control study,” Hepatology, vol. 59, no. 4, pp. 1482–1491, 2014.
[12] M. Martineau, C. Raker, R. Powrie, and C. Williamson, “Intrahepatic cholestasis of pregnancy is associated with an increased risk of gestational diabetes,” European Journal of Obstetrics, Gynecology, and Reproductive Biology, vol. 176, no. 1, pp. 80–85, 2014.
[13] M. G. Martineau, C. Raker, P. H. Dixon et al., “The metabolic profile of intrahepatic cholestasis of pregnancy is associated with impaired glucose tolerance, dyslipidemia, and increased fetal growth,” Diabetes Care, vol. 38, no. 2, pp. 243–248, 2015.
[14] J. Wójcicka-Jagodzińska, J. Kuczyńska-Siczewska, K. Czajkowska, and R. Smolarczyk, “Carbohydrate metabolism in the course of intrahepatic cholestasis in pregnancy,” American Journal of Obstetrics and Gynecology, vol. 161, no. 4, pp. 959–964, 1989.
[15] E. W. Shemer, H. U. Marschall, J. F. Ludvigsson, and O. Stephansson, “Intrahepatic cholestasis of pregnancy and associated adverse pregnancy and fetal outcomes: a 12-year population-based cohort study,” BJOG: An International Journal of Obstetrics & Gynaecology, vol. 120, no. 6, pp. 717–723, 2013.
[16] Y. Bacq, M. le Besco, A. I. Lecuyer et al., “Ursodeoxycholic acid therapy in intrahepatic cholestasis of pregnancy: results in real-world conditions and factors predictive of response to...
treatment,” *Digestive and Liver Disease*, vol. 49, no. 1, pp. 63–69, 2017.

[17] L. C. Chappell, J. L. Bell, A. Smith et al., “Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial,” *The Lancet*, vol. 394, no. 10201, pp. 849–860, 2019.

[18] G. Castaño, S. Lucangioli, S. Sookoian et al., “Bile acid profiles by capillary electrophoresis in intrahepatic cholestasis of pregnancy,” *Clinical Science*, vol. 110, no. 4, pp. 459–465, 2006.

[19] M. Lunzer, P. Barnes, K. Byth, and M. O’Halloran, “Serum bile acid concentrations during pregnancy and their relationship to obstetric cholestasis,” *Gastroenterology*, vol. 91, no. 4, pp. 825–829, 1986.

[20] M. J. Pascual, M. A. Serrano, M. Y. El-Mir, R. I. R. Macias, F. Jiménez, and J. J. G. Marin, “Relationship between asymptomatic hypercholaenaemia of pregnancy and progesterone metabolism,” *Clinical Science*, vol. 102, no. 5, pp. 587–593, 2002.

[21] K. Wisner, “Gestational hypertension and preeclampsia,” *MCN: The American Journal of Maternal/Child Nursing*, vol. 44, no. 3, pp. 170, 2019.

[22] L. A. Magee, A. Pels, M. Helewa et al., “Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary,” *Journal of Obstetrics and Gynaecology Canada*, vol. 36, no. 5, pp. 416–438, 2014.

[23] International Association of Diabetes and Pregnancy Study Groups Consensus Panel, “International Association of Diabetes and Pregnancy Study Groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy,” *Diabetes Care*, vol. 33, no. 3, pp. 676–682, 2010.

[24] M. C. Lu, M. Fridman, L. M. Korst et al., “Variations in the incidence of postpartum hemorrhage across hospitals in California,” *Maternal and Child Health Journal*, vol. 9, no. 3, pp. 297–306, 2005.

[25] X. X. Gao, M. Y. Ye, Y. Liu et al., “Prevalence and risk factors of intrahepatic cholestasis of pregnancy in a Chinese population,” *Scientific Reports*, vol. 10, no. 1, pp. 16307–16307, 2020.

[26] A. P. Kenyon, C. N. Piercy, J. Girling, C. Williamson, R. M. Tribe, and A. H. Shennan, “Obstetric cholestasis, outcome with active management: a series of 70 cases,” *BJOG: An International Journal of Obstetrics and Gynaecology*, vol. 109, no. 3, pp. 282–288, 2002.

[27] D. G. Goulis, I. A. L. Walker, M. de Swiet, C. W. G. Redman, and C. Williamson, “Preeclampsia with abnormal liver function tests is associated with cholestasis in a subgroup of cases,” *Hypertension in Pregnancy*, vol. 23, no. 1, pp. 19–27, 2009.

[28] M. Mor, A. Shmuelli, E. Krispin et al., “Intrahepatic cholestasis of pregnancy as a risk factor for preeclampsia,” *Archives of Gynecology and Obstetrics*, vol. 301, no. 3, pp. 655–664, 2020.

[29] W. H. Sepúlveda, C. González, M. A. Cruz, and M. I. Rudolph, “Vasoconstrictive effect of bile acids on isolated human placental chorionic veins,” *European Journal of Obstetrics, Gynecology, and Reproductive Biology*, vol. 42, no. 3, pp. 211–215, 1991.

[30] D. P. Kumar, S. Rajagopal, S. Mahavadi et al., “Activation of transmembrane bile acid receptor TGR5 stimulates insulin secretion in pancreatic β cells,” *Biochemical and Biophysical Research Communications*, vol. 427, no. 3, pp. 600–605, 2012.

[31] K. Ma, P. K. Saha, L. Chan, and D. D. Moore, “Farnesoid X receptor is essential for normal glucose homeostasis,” *The Journal of Clinical Investigation*, vol. 116, no. 4, pp. 1102–1109, 2006.

[32] T. Li and J. Y. L. Chiang, “Bile acid signaling in liver metabolism and diseases,” *Journal of Lipids*, vol. 2012, 9 pages, 2012.

[33] H. Duboc, Y. Taché, and A. F. Hofmann, “The bile acid TGR5 membrane receptor: from basic research to clinical application,” *Digestive and Liver Disease*, vol. 46, no. 4, pp. 302–312, 2014.

[34] E. A. Wikström Shemer, M. Thorsell, H. U. Marschall, and M. Kajiser, “Risks of emergency cesarean section and fetal asphyxia after induction of labor in intrahepatic cholestasis of pregnancy: a hospital-based retrospective cohort study,” *Sexual & Reproductive Healthcare*, vol. 4, no. 1, pp. 17–22, 2013.

[35] D. Cui, Y. Zhong, L. Zhang, and H. Du, “Bile acid levels and risk of adverse perinatal outcomes in intrahepatic cholestasis of pregnancy: a meta-analysis,” *The Journal of Obstetrics and Gynaecology Research*, vol. 43, no. 9, pp. 1411–1420, 2017.

[36] C. ovadia, P. T. Seed, A. Sklavounos et al., “Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses,” *The Lancet*, vol. 393, no. 10174, pp. 899–909, 2019.

[37] G. A. Campos, R. J. Castillo, and F. G. Toro, “Effect of bile acids on the myometrial contractility of the isolated pregnant uterus,” *Revista chilena de obstetricia y ginecologia*, vol. 53, no. 4, pp. 229–233, 1988.

[38] A. M. Germain, S. Kato, J. A. Carvajal, G. J. Valenzuela, G. L. Valdes, and J. C. Glasinovic, “Bile acids increase response and expression of human myometrial oxytocin receptor,” *American Journal of Obstetrics and Gynecology*, vol. 189, no. 2, pp. 577–582, 2003.

[39] G. Page, I. Dehaene, and A. S. Page, “Induction for intrahepatic cholestasis of pregnancy: why we’ll never know,” *American Journal of Obstetrics and Gynecology*, vol. 213, no. 4, pp. 593–594, 2015.

[40] T. Kawakita, L. I. Parikh, P. S. Ramsey et al., “Predictors of adverse neonatal outcomes in intrahepatic cholestasis of pregnancy,” *American Journal of Obstetrics and Gynecology*, vol. 213, no. 4, pp. 570.e1–570.e8, 2015.

[41] C. Arthuis, C. Diguisto, H. Lorphelin et al., “Perinatal outcomes of intrahepatic cholestasis during pregnancy: an 8-year case-control study,” *PLoS One*, vol. 15, no. 2, p. e0228213, 2020.

[42] M. J. Bicocca, J. D. Sperling, and S. P. Chauhan, “Intrahepatic cholestasis of pregnancy: review of six national and regional guidelines,” *European Journal of Obstetrics, Gynecology, and Reproductive Biology*, vol. 231, pp. 180–187, 2018.

[43] Y. Bacq, L. Sentilhes, H. B. Reyes et al., “Efficacy of ursodeoxycholic acid in treating intrahepatic cholestasis of pregnancy: a meta-analysis,” *Gastroenterology*, vol. 143, no. 6, pp. 1492–1501, 2012.

[44] L. C. Chappell, V. Gurung, P. T. Seed et al., “Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial,” *BMJ*, vol. 344, no. 6, pp. 6228, 2012.

[45] L. Yuling, Q. Fuyuan, L. Haiyi, and L. Dayan, “Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy,” *Journal of Huazhong University of Science and Technology. Medical Sciences*, vol. 26, no. 3, pp. 350–352, 2006.
[46] A. Glantz, H. U. Marschall, F. Lammert, and L. Å. Mattsson, “Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid,” *Hepatology*, vol. 42, no. 6, pp. 1399–1405, 2005.

[47] J. Palma, H. Reyes, J. Ribalta et al., “Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized double-blind study controlled with placebo,” *Journal of Hepatology*, vol. 27, no. 6, pp. 1022–1028, 1997.